

# MERCK & CO., INC.

## **FORM 8-K** (Current report filing)

Filed 07/28/17 for the Period Ending 07/28/17

Address	126 EAST LINCOLN AVENUE P.O. BOX 2000 RAHWAY, NJ, 07065
Telephone	908-740-4000
CIK	0000310158
Symbol	MRK
SIC Code	2834 - Pharmaceutical Preparations
Industry	Pharmaceuticals
Sector	Healthcare
Fiscal Year	12/31

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **July 28, 2017**

**Merck & Co., Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**New Jersey**

(State or Other Jurisdiction of Incorporation)

**1-6571**

(Commission File Number)

**22-1918501**

(I.R.S. Employer Identification No.)

**2000 Galloping Hill Road, Kenilworth, NJ**

(Address of Principal Executive Offices)

**07033**

(Zip Code)

Registrant's Telephone Number, Including Area Code **(908) 740-4000**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§204.12b-2 of this chapter)

- ☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

---

Item 2.02. Results of Operations and Financial Condition .

The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.

Incorporated by reference is a press release issued by the Registrant on July 28, 2017, regarding earnings for the second quarter of 2017, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.

This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit 99.1	Press release issued July 28, 2017, regarding earnings for the second quarter of 2017
--------------	---

Exhibit 99.2	Certain supplemental information not included in the press release
--------------	--

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Merck & Co., Inc.

Date: July 28, 2017

By: /s/ Karen L. Mealey  
KAREN L. MEALEY  
Assistant Secretary

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press release issued July 28, 2017, regarding earnings for the second quarter of 2017
99.2	Certain supplemental information not included in the press release

**FOR IMMEDIATE RELEASE**

Media Contacts: Tracy Ogden  
(908) 740-1747

Claire Gillespie  
(267) 305-0932

Investor Contacts: Teri Loxam  
(908) 740-1986

Amy Klug  
(908) 740-1898

**Merck Announces Second-Quarter 2017 Financial Results**

- Second-Quarter 2017 Worldwide Sales Were \$9.9 Billion, an Increase of 1 Percent, Including a 1 Percent Negative Impact from Foreign Exchange
- Second-Quarter 2017 GAAP EPS Was \$0.71; Second-Quarter Non-GAAP EPS Was \$1.01
- Company Narrows and Raises 2017 Full-Year Revenue Range to be Between \$39.4 Billion and \$40.4 Billion, Including an Approximately 1 Percent Negative Impact from Foreign Exchange
- Company Reduces 2017 Full-Year GAAP EPS Range to be Between \$1.60 and \$1.72; Continues to Expect 2017 Full-Year Non-GAAP EPS Range to be Between \$3.76 and \$3.88, Including an Approximately 1 Percent Negative Impact from Foreign Exchange
- KEYTRUDA Development Program Significantly Advances with Several Key Regulatory Approvals
- Merck Enters Global Strategic Oncology Collaboration with AstraZeneca

KENILWORTH, N.J., July 28, 2017 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2017.

“We continued to deliver strong results in the second quarter, driven by robust momentum for KEYTRUDA and good progress with other products in our portfolio,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “The company continues to invest in innovative science that addresses the critical needs of population health, which benefits patients while creating long-term value for shareholders.”

## Financial Summary

\$ in millions, except EPS amounts	Second Quarter	
	2017	2016
Sales	\$9,930	\$9,844
GAAP net income <sup>1</sup>	1,946	1,205
Non-GAAP net income that excludes items listed below <sup>1,2</sup>	2,778	2,587
GAAP EPS	0.71	0.43
Non-GAAP EPS that excludes items listed below <sup>2</sup>	1.01	0.93

Worldwide sales were \$9.9 billion for the second quarter of 2017, an increase of 1 percent compared with the second quarter of 2016, including a 1 percent negative impact from foreign exchange.

GAAP (generally accepted accounting principles) earnings per share assuming dilution (EPS) were \$0.71 for the second quarter of 2017. Non-GAAP EPS of \$1.01 for the second quarter of 2017 excludes acquisition- and divestiture-related costs, restructuring costs and certain other items. Year-to-date results can be found in the attached tables.

## Pipeline Highlights

Merck made significant advances in the development program for KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, receiving key regulatory approvals and a supplemental Biologics License Application (sBLA) acceptance.

- The U.S. Food and Drug Administration (FDA) approved KEYTRUDA under its Accelerated Approval program:
  - In combination with pemetrexed and carboplatin for the treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC) regardless of PD-L1 expression. This is the first regulatory approval of KEYTRUDA in combination with another treatment. The National Cancer Care Network (NCCN) also recommended the combination for the treatment of patients with metastatic nonsquamous NSCLC.
  - For the treatment of previously treated patients with advanced microsatellite instability-high cancers.

<sup>1</sup> Net income attributable to Merck & Co., Inc.

<sup>2</sup> Merck is providing certain 2017 and 2016 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Senior management's annual compensation is derived in part using non-GAAP income and non-GAAP EPS. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the items, see Table 2a attached to this release.

- For the treatment of certain patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer, for first-line use in patients who are ineligible for cisplatin-containing therapy.
- The FDA approved KEYTRUDA for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma in the second-line setting for patients who have disease progression during or following platinum-containing chemotherapy.
- The European Commission approved KEYTRUDA for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV.
- The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of KEYTRUDA for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma, with a final decision expected in the third quarter of 2017.
- The FDA accepted for review the sBLA for KEYTRUDA for the treatment of patients with recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have already received two or more lines of chemotherapy. The FDA granted Priority Review with a PDUFA action date of Sept. 22, 2017.
- The FDA granted Breakthrough Therapy Designation for KEYTRUDA in combination with axitinib as a first-line treatment for patients with advanced or metastatic renal cell carcinoma.

The company previously announced that the pivotal Phase 3 KEYNOTE-040 trial investigating KEYTRUDA in previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma did not meet its primary endpoint of overall survival (HR, 0.82 [95% CI, 0.67-1.01]; one-sided p = 0.03). The safety profile observed in KEYNOTE-040 was consistent with that observed in previously reported studies of KEYTRUDA without new safety signals identified. The final data from KEYNOTE-040 will be presented at an upcoming medical meeting.

At the 77<sup>th</sup> Scientific Sessions of the American Diabetes Association, Merck in partnership with Pfizer presented data from two Phase 3 studies of ertugliflozin, an investigational oral SGLT-2 inhibitor in development to help improve glycemic control in adults with type 2 diabetes, which met their primary endpoints. Three New Drug Applications for medicines containing ertugliflozin are currently under review with the FDA and EMA.



Phase 3 results from the REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid modification) outcomes study of anacetrapib met its primary endpoint, significantly reducing major coronary events (defined as the composite of coronary death, myocardial infarction, and coronary revascularization) compared to placebo in patients at risk for cardiac events who are already receiving an effective LDL-C lowering regimen. The safety profile of anacetrapib in the early analysis was generally consistent with that demonstrated in previous studies of the drug, including accumulation of anacetrapib in adipose tissue, as has been previously reported. Merck plans to review the results of the trial with external experts, and will consider whether to file new drug applications with the FDA and other regulatory agencies.

New data from the company's HIV portfolio and pipeline were presented at the 9th IAS Conference on HIV Science.

- Week 96 results from the pivotal Phase 3 ONCEMRK study evaluating the efficacy and safety of ISENTRESS HD, a 1200 mg once-daily dose of the company's integrase inhibitor, ISENTRESS (raltegravir), met its primary efficacy endpoint of non-inferiority to twice-daily ISENTRESS, with a similar safety and tolerability profile, reaffirming the comparable efficacy and safety of ISENTRESS HD. ISENTRESS HD is now approved in the United States and European Union.
- 48 week data from DRIVE-AHEAD, the second of two pivotal Phase 3 studies evaluating doravirine (MK-1439), an investigational non-nucleoside reverse transcriptase inhibitor, for the treatment of HIV-1 infection showed that a once-daily single tablet, fixed-dose combination of doravirine, lamivudine and tenofovir disoproxil fumarate met its primary endpoint. Based on these findings the company plans to file regulatory applications in the fourth quarter of 2017.
- Results from a Phase 1 study of MK-8591, Merck's investigational nucleoside reverse transcriptase translocation inhibitor in adult patients with HIV-1 infection.

Merck entered into an exclusive worldwide license agreement with Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical antibody candidate targeting the protein tau . Changes in tau are associated with a number of diseases affecting the nervous system, including Alzheimer's disease.

### **Recent Developments**

Merck entered a global strategic oncology collaboration with AstraZeneca to co-develop and co-commercialize AstraZeneca's Lynparza (olaparib), a PARP inhibitor, and investigational medicine selemetinib, a MEK inhibitor, as monotherapy and in combination treatments for

multiple cancer types. Merck and AstraZeneca will independently develop and commercialize Lynparza and selumetinib in combinations with the companies' respective PD-1 and PD-L1 immuno-oncology medicines KEYTRUDA and Imfinzi (durvalumab). The companies will share development and marketing costs equally, as well as gross profits from Lynparza and selumetinib.

## Second-Quarter Revenue Performance

The following table reflects sales of the company's top pharmaceutical products, as well as total sales of Animal Health products.

\$ in millions	Second Quarter			
	2017	2016	Change	Change Ex-Exchange
Total Sales	\$9,930	\$9,844	1%	2%
Pharmaceutical	8,759	8,700	1%	2%
JANUVIA / JANUMET	1,511	1,634	-8%	-7%
KEYTRUDA	881	314	180%	183%
ZETIA / VYTORIN	549	994	-45%	-44%
ZEPATIER	517	112	*	*
GARDASIL / GARDASIL 9	469	393	19%	20%
PROQUAD, M-M-R II and VARIVAX	399	383	4%	5%
ISENTRESS / ISENTRESS HD	282	338	-17%	-15%
REMICADE	208	339	-39%	-36%
SINGULAIR	203	229	-11%	-10%
Animal Health	955	900	6%	7%
Other Revenues	216	244	-11%	-5%

\* Growth comparison not meaningful due to ongoing product launch.

## Pharmaceutical Revenue

Second-quarter pharmaceutical sales increased 1 percent to \$8.8 billion, including a 1 percent negative impact from foreign exchange. The growth was primarily driven by product launches and vaccines, largely offset by the loss of market exclusivity for several products, as well as lower sales in the diabetes franchise.

Growth in oncology was due to higher sales of KEYTRUDA as the company continues to launch the product with new indications globally. Strong momentum from NSCLC, as KEYTRUDA is the only anti-PD-1 approved in the first-line setting, contributed significantly to KEYTRUDA's overall growth.

Growth in hepatitis C was driven by ZEPATIER (elbasvir and grazoprevir), a medicine for the treatment of chronic hepatitis C virus genotypes 1 or 4 infection, due to ongoing launches globally.

Additionally, the ongoing launch of BRIDION (sugammadex) Injection 100 mg/mL, a medicine for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults undergoing surgery, generated sales of \$163 million and also contributed to growth during the second quarter of 2017.

Growth in vaccines was primarily driven by higher sales of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] and GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), vaccines to prevent certain cancers and other diseases caused by HPV, reflecting strong demand in Asia Pacific and the timing of sales in Brazil. Growth in vaccines also reflects higher sales of PNEUMOVAX 23 (pneumococcal vaccine polyvalent), a vaccine to help prevent pneumococcal disease, largely driven by volume growth and pricing in the United States. Additionally, vaccines sales growth reflects incremental sales of approximately \$70 million, of which approximately \$40 million relates to GARDASIL and GARDASIL 9, due to the recording of vaccine sales from 19 European countries that were part of the Sanofi Pasteur MSD (SPMSD) vaccines joint venture, which was terminated on Dec. 31, 2016.

Pharmaceutical sales reflect a decrease in the diabetes franchise of JANUVIA and JANUMET (sitagliptin and metformin HCl), medicines that help lower blood sugar in adults with type 2 diabetes, primarily due to lower sales in the United States, reflecting continued pricing pressure and lower customer inventory levels that were partially offset by continued volume growth. Pharmaceutical sales growth also was offset by the loss of U.S. market exclusivity for ZETIA (ezetimibe) in late 2016 and VYTORIN (ezetimibe/simvastatin) in April 2017, medicines for lowering LDL cholesterol, and the ongoing impacts of generic competition for CUBICIN (daptomycin for injection), an I.V. antibiotic, and biosimilar competition for REMICADE (infliximab), a treatment for inflammatory diseases, in the company's marketing territories in Europe. In the aggregate, sales of these products declined \$830 million during the second quarter of 2017 compared to the second quarter of 2016.

### **Animal Health Revenue**

Animal Health sales totaled \$955 million for the second quarter of 2017, an increase of 6 percent compared with the second quarter of 2016, including a 1 percent negative impact from foreign exchange. Growth was primarily due to sales increases in companion animal products,

driven by the BRAVECTO (fluralaner) line of products that kill fleas and ticks in dogs and cats for up to 12 weeks, and the NOBIVAC Canine Flu Bivalent vaccine, as well as sales increases in ruminants products, reflecting the positive impact of the Vallée S.A. acquisition.

## Second-Quarter Expense, EPS and Related Information

The table below presents selected expense information.

	GAAP	Acquisition- and Divestiture- Related Costs <sup>3</sup>	Restructuring Costs	Non-GAAP <sup>2</sup>
<b>Second-Quarter 2017</b>				
Materials and production	\$3,080	\$827	\$33	\$2,220
Marketing and administrative	2,438	9	2	2,427
Research and development	1,749	7	9	1,733
Restructuring costs	166	—	166	—
Other (income) expense, net	58	39	—	19
<b>Second-Quarter 2016</b>				
Materials and production	\$3,578	\$1,120	\$66	\$2,392
Marketing and administrative	2,458	18	87	2,353
Research and development	2,151	207	64	1,880
Restructuring costs	134	—	134	—
Other (income) expense, net	19	—	—	19

## GAAP Expense, EPS and Related Information

On a GAAP basis, the gross margin was 69.0 percent for the second quarter of 2017 compared to 63.7 percent for the second quarter of 2016. The increase in gross margin for the second quarter of 2017 was primarily driven by lower acquisition- and divestiture-related costs and restructuring costs, which reduced gross margin by 8.6 percentage points in the second quarter of 2017 compared with 12.0 percentage points in the second quarter of 2016. The increase also reflects the favorable effects of product mix and lower inventory write-offs.

Marketing and administrative expenses were \$2.4 billion in the second quarter of 2017, a 1 percent decrease compared to the second quarter of 2016. The decrease primarily reflects lower restructuring costs partially offset by higher administrative costs including costs associated with the company now operating its European vaccines business in the countries that were part of the SPMSD vaccines joint venture, which was terminated on Dec. 31, 2016, and higher promotion expenses related to product launches.

<sup>3</sup> Includes expenses for the amortization of intangible assets and purchase accounting adjustments to inventories recognized as a result of acquisitions, intangible asset impairment charges and expense or income related to changes in the estimated fair value measurement of contingent consideration. Also includes integration, transaction and certain other costs related to business acquisitions and divestitures.

Research and development (R&D) expenses were \$1.7 billion in the second quarter of 2017, a 19 percent decrease compared to the second quarter of 2016. The decrease primarily reflects lower intangible asset impairment charges and licensing costs.

GAAP EPS was \$0.71 for the second quarter of 2017 compared with \$0.43 for the second quarter of 2016.

#### **Non-GAAP Expense, EPS and Related Information**

The non-GAAP gross margin was 77.6 percent for the second quarter of 2017 compared to 75.7 percent for the second quarter of 2016. The increase in non-GAAP gross margin was largely driven by the favorable effects of product mix and lower inventory write-offs.

Non-GAAP marketing and administrative expenses were \$2.4 billion in the second quarter of 2017, an increase of 3 percent compared to the second quarter of 2016. The increase was driven primarily by higher administrative costs, including costs associated with the company now operating its European vaccines business in the countries that were previously part of the SPMSD vaccines joint venture, and higher promotion expenses related to product launches.

Non-GAAP R&D expenses were \$1.7 billion in the second quarter of 2017, an 8 percent decrease compared to the second quarter of 2016. The decrease primarily reflects lower licensing costs.

Non-GAAP EPS was \$1.01 for the second quarter of 2017 compared with \$0.93 for the second quarter of 2016.

A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that follows.

\$ in millions, except EPS amounts	Second Quarter	
	2017	2016
<b>EPS</b>		
GAAP EPS	\$0.71	\$0.43
Difference <sup>4</sup>	0.30	0.50
Non-GAAP EPS that excludes items listed below <sup>2</sup>	\$1.01	\$0.93
<b>Net Income</b>		
GAAP net income <sup>1</sup>	\$1,946	\$1,205
Difference	832	1,382
Non-GAAP net income that excludes items listed below <sup>1,2</sup>	\$2,778	\$2,587
<b>Decrease (Increase) in Net Income Due to Excluded Items:</b>		
Acquisition- and divestiture-related costs <sup>3</sup>	\$882	\$1,345
Restructuring costs	210	351
Net decrease (increase) in income before taxes	1,092	1,696
Income tax (benefit) expense <sup>5</sup>	(260)	(314)
Decrease (increase) in net income	\$832	\$1,382

## Financial Outlook

On June 27, 2017, the company experienced a network cyber-attack that led to a disruption of its worldwide operations, including manufacturing, research and sales operations. While the company does not yet know the magnitude of the impact of the disruption, which remains ongoing in certain operations, it continues to work to minimize the effects.

The company is in the process of restoring its manufacturing operations. To date, Merck has largely restored its packaging operations and has partially restored its formulation operations. The company is in the process of restoring its Active Pharmaceutical Ingredient operations but is not yet producing bulk product. The company's external manufacturing was not impacted. Throughout this time, Merck has continued to fulfill orders and ship product.

The company is confident in the continuous supply of key products such as KEYTRUDA, JANUVIA and ZEPATIER. In addition, Merck does not currently expect a significant impact to sales of its other top products; however, the company anticipates that it will have temporary delays in fulfilling orders for certain other products in certain markets.

The financial outlook below reflects the current state of the company's manufacturing operations as well as its plans to restore those operations and potential costs associated with the remediation efforts.

Merck has reduced its full-year 2017 GAAP EPS range to be between \$1.60 and \$1.72. The change in the GAAP EPS range reflects the inclusion of licensing expenses related to the collaboration with AstraZeneca. Merck has maintained its full-year 2017 non-GAAP EPS range

<sup>4</sup> Represents the difference between calculated GAAP EPS and calculated non-GAAP EPS, which may be different than the amount calculated by dividing the impact of the excluded items by the weighted-average shares for the period.

<sup>5</sup> Includes the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments, as well as a benefit of \$88 million related to the settlement of a state income tax issue.

to be between \$3.76 and \$3.88, including an approximately 1 percent negative impact from foreign exchange at mid-July 2017 exchange rates. The non-GAAP range excludes acquisition- and divestiture-related costs, costs related to restructuring programs and certain other items, including licensing expenses related to the collaboration with AstraZeneca as shown in the table below.

Merck has narrowed and raised its full-year 2017 revenue range to be between \$39.4 billion and \$40.4 billion , including an approximately 1 percent negative impact from foreign exchange at mid-July 2017 exchange rates.

The following table summarizes the company's 2017 financial guidance.

	GAAP	Non-GAAP <sup>2</sup>
Revenue	\$39.4 to \$40.4 billion	\$39.4 to \$40.4 billion**
Operating expenses	Lower than 2016	Higher than 2016 by a mid-single digit rate
Effective tax rate	32.0% to 33.0%	21.0% to 22.0%
EPS	\$1.60 to \$1.72	\$3.76 to \$3.88

\*\*The company does not have any non-GAAP adjustments to revenue.

A reconciliation of anticipated 2017 GAAP EPS to non-GAAP EPS and the items excluded from non-GAAP EPS are provided in the table below.

\$ in millions, except EPS amounts	Full-Year 2017
GAAP EPS	\$1.60 to \$1.72
Difference <sup>4</sup>	2.16
Non-GAAP EPS that excludes items listed below <sup>2</sup>	\$3.76 to \$3.88
Acquisition- and divestiture-related costs	\$3,600
Restructuring costs	600
Licensing expense relating to AstraZeneca collaboration	2,350
Net decrease (increase) in income before taxes	6,550
Estimated income tax (benefit) expense	(610)
Decrease (increase) in net income	\$5,940

The expected full-year 2017 GAAP effective tax rate of 32.0 to 33.0 percent reflects an unfavorable impact of approximately 11 percentage points from the above items.

#### Total Employees

As of June 30, 2017, Merck had approximately 69,000 employees worldwide.

## Earnings Conference Call

Investors, journalists and the general public may access a live audio webcast of the call today at 8:00 a.m. EDT on Merck's website at <http://investors.merck.com/events-and-presentations/default.aspx>. Institutional investors and analysts can participate in the call by dialing (706) 758-9927 or (877) 381-5782 and using ID code number 36593115. Members of the media are invited to monitor the call by dialing (706) 758-9928 or (800) 399-7917 and using ID code number 36593115. Journalists who wish to ask questions are requested to contact a member of Merck's Media Relations team at the conclusion of the call.

## About Merck

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information, visit [www.merck.com](http://www.merck.com) and connect with us on [Twitter](#), [Facebook](#), [YouTube](#) and [LinkedIn](#). You can also follow our Twitter conversation at \$MRK.

## Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate



fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2016 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ([www.sec.gov](http://www.sec.gov)).

###

**MERCK & CO., INC.**  
**CONSOLIDATED STATEMENT OF INCOME - GAAP**  
**(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)**  
**(UNAUDITED)**  
**Table 1**

	GAAP			GAAP		
	2Q17	2Q16	% Change	June YTD 2017	June YTD 2016	% Change
Sales	\$ 9,930	\$ 9,844	1%	\$ 19,365	\$ 19,156	1%
Costs, Expenses and Other						
Materials and production <sup>(1)</sup>	3,080	3,578	-14%	6,095	7,150	-15%
Marketing and administrative <sup>(1)</sup>	2,438	2,458	-1%	4,849	4,776	2%
Research and development <sup>(1)</sup>	1,749	2,151	-19%	3,545	3,810	-7%
Restructuring costs <sup>(2)</sup>	166	134	24%	317	225	41%
Other (income) expense, net <sup>(1)</sup>	58	19	*	117	67	75%
Income Before Taxes	2,439	1,504	62%	4,442	3,128	42%
Taxes on Income	488	295		935	789	
Net Income	1,951	1,209	61%	3,507	2,339	50%
Less: Net Income Attributable to Noncontrolling Interests	5	4		11	9	
Net Income Attributable to Merck & Co., Inc.	\$ 1,946	\$ 1,205	61%	\$ 3,496	\$ 2,330	50%
Earnings per Common Share Assuming Dilution	\$ 0.71	\$ 0.43	65%	\$ 1.27	\$ 0.83	53%
Average Shares Outstanding Assuming Dilution	2,752	2,789		2,759	2,792	
Tax Rate	20.0%	19.6%		21.0%	25.2%	

\* 100% or greater

(1) Amounts include the impact of acquisition and divestiture-related costs, restructuring costs and certain other items. See accompanying tables for details.

(2) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs.

**MERCK & CO., INC.**  
**GAAP TO NON-GAAP RECONCILIATION**  
**SECOND QUARTER 2017**  
**(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)**  
**(UNAUDITED)**  
**Table 2a**

	GAAP	Acquisition and Divestiture-Related Costs <sup>(1)</sup>	Restructuring Costs <sup>(2)</sup>	Certain Other Items	Adjustment Subtotal	Non-GAAP
Materials and production	\$ 3,080	827	33		860	\$ 2,220
Marketing and administrative	2,438	9	2		11	2,427
Research and development	1,749	7	9		16	1,733
Restructuring costs	166		166		166	—
Other (income) expense, net	58	39			39	19
Income Before Taxes	2,439	(882)	(210)		(1,092)	3,531
Income Tax Provision (Benefit)	488	(127) <sup>(3)</sup>	(45) <sup>(3)</sup>	(88) <sup>(4)</sup>	(260)	748
Net Income	1,951	(755)	(165)	88	(832)	2,783
Net Income Attributable to Merck & Co., Inc.	1,946	(755)	(165)	88	(832)	2,778
Earnings per Common Share Assuming Dilution	\$ 0.71	(0.27)	(0.06)	0.03	(0.30)	\$ 1.01
Tax Rate	20.0%					21.2%

Only the line items that are affected by non-GAAP adjustments are shown.

Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Senior management's annual compensation is derived in part using non-GAAP income and non-GAAP EPS. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs primarily reflect \$779 million of expenses for the amortization of intangible assets recognized as a result of acquisitions, as well as intangible asset impairment charges of \$47 million. Amounts included in marketing and administrative expenses reflect integration, transaction and certain other costs related to business acquisitions and divestitures. Amounts included in research and development expenses reflect changes in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in other (income) expense, net primarily reflect changes in the estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.

(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.

(4) Represents a benefit related to the settlement of a state income tax issue.

**MERCK & CO., INC.**  
**GAAP TO NON-GAAP RECONCILIATION**  
**SIX MONTHS ENDED JUNE 30, 2017**  
**(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)**  
**(UNAUDITED)**  
**Table 2b**

	<u>GAAP</u>	<u>Acquisition and Divestiture-Related Costs <sup>(1)</sup></u>	<u>Restructuring Costs <sup>(2)</sup></u>	<u>Certain Other Items</u>	<u>Adjustment Subtotal</u>	<u>Non-GAAP</u>
Materials and production	\$ 6,095	1,682	96		1,778	\$ 4,317
Marketing and administrative	4,849	29	3		32	4,817
Research and development	3,545	18	9		27	3,518
Restructuring costs	317		317		317	—
Other (income) expense, net	117	36		(9)	27	90
Income Before Taxes	4,442	(1,765)	(425)	9	(2,181)	6,623
Income Tax Provision (Benefit)	935	(285) <sup>(3)</sup>	(93) <sup>(3)</sup>	(85) <sup>(3)</sup>	(463)	1,398
Net Income	3,507	(1,480)	(332)	94	(1,718)	5,225
Net Income Attributable to Merck & Co., Inc.	3,496	(1,480)	(332)	94	(1,718)	5,214
Earnings per Common Share Assuming Dilution	\$ 1.27	(0.53)	(0.12)	0.03	(0.62)	\$ 1.89
Tax Rate	21.0%					21.1%

Only the line items that are affected by non-GAAP adjustments are shown.

Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Senior management's annual compensation is derived in part using non-GAAP income and non-GAAP EPS. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs primarily reflect \$1.6 billion of expenses for the amortization of intangible assets recognized as a result of acquisitions, as well as intangible asset impairment charges of \$123 million. Amounts included in marketing and administrative expenses reflect integration, transaction and certain other costs related to business acquisitions and divestitures. Amounts included in research and development expenses primarily reflect changes in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in other (income) expense, net primarily reflect changes in the estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.

(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments, as well as a benefit of \$88 million related to the settlement of a state income tax issue.

**MERCK & CO., INC.**  
**FRANCHISE / KEY PRODUCT SALES**  
**(AMOUNTS IN MILLIONS)**

**Table 3**

	2017			2016						2Q		June YTD	
	1Q	2Q	June YTD	1Q	2Q	June YTD	3Q	4Q	Full Year	Nom %	Ex-Exch %	Nom %	Ex-Exch %
TOTAL SALES <sup>(1)</sup>	\$ 9,434	\$ 9,930	\$ 19,365	\$ 9,312	\$ 9,844	\$ 19,156	\$ 10,536	\$ 10,115	\$ 39,807	1	2	1	2
<b>PHARMACEUTICAL</b>	<b>8,185</b>	<b>8,759</b>	<b>16,944</b>	<b>8,104</b>	<b>8,700</b>	<b>16,804</b>	<b>9,443</b>	<b>8,904</b>	<b>35,151</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>2</b>
<b>Primary Care and Women's Health</b>													
Cardiovascular													
Zetia	334	367	701	612	702	1,314	671	575	2,560	-48	-47	-47	-46
Vytorin	241	182	423	277	293	570	273	299	1,141	-38	-37	-26	-25
Liptruzet	49	63	112	23	33	56	39	50	146	88	90	99	102
Adempas	84	67	151	33	40	72	48	49	169	68	69	109	110
Diabetes													
Januvia	839	948	1,787	906	1,064	1,970	1,006	932	3,908	-11	-10	-9	-9
Janumet	496	563	1,059	506	569	1,075	548	577	2,201	-1	0	-2	-1
General Medicine & Women's Health													
NuvaRing	160	199	359	175	200	376	195	207	777	0	0	-4	-4
Implanon / Nexplanon	170	178	349	134	164	298	148	160	606	9	9	17	18
Follistim AQ	81	79	160	94	73	167	101	87	355	9	10	-4	-3
<b>Hospital and Specialty</b>													
Hepatitis													
Zepatier	378	517	895	50	112	161	164	229	555	*	*	*	*
HIV													
Isentress / Isentress HD	305	282	587	340	338	678	372	337	1,387	-17	-15	-13	-13
Hospital Acute Care													
Bridion	148	163	310	90	113	204	139	139	482	44	44	52	53
Noxafil	141	155	296	145	143	288	147	161	595	8	11	3	5
Invanz	136	150	286	114	143	257	152	152	561	5	5	11	11
Cancidas	121	112	233	133	131	263	142	152	558	-14	-13	-12	-9
Cubicin	96	103	198	292	357	649	320	119	1,087	-71	-71	-69	-69
Primaxin	62	71	133	73	81	154	77	66	297	-13	-9	-14	-10
Immunology													
Remicade	229	208	437	349	339	688	311	269	1,268	-39	-36	-37	-34
Simponi	184	199	383	188	199	387	193	186	766	0	3	-1	3
<b>Oncology</b>													
Keytruda	584	881	1,465	249	314	563	356	483	1,402	180	183	160	162
Emend	133	143	276	126	143	268	137	144	549	0	1	3	3
Temodar	66	65	130	66	73	139	78	67	283	-12	-11	-6	-6
<b>Diversified Brands</b>													
Respiratory													
Singular	186	203	389	237	229	465	239	210	915	-11	-10	-16	-16
Nasonex	139	85	224	229	101	331	94	112	537	-16	-16	-32	-33
Dulera	82	69	151	113	121	234	97	105	436	-43	-43	-35	-36
Other													
Cozaar / Hyzaar	112	119	231	126	132	258	131	121	511	-10	-7	-10	-8
Aroclia	103	89	192	111	117	228	114	108	450	-24	-24	-16	-15
Fosamax	61	66	127	75	73	148	68	68	284	-10	-9	-14	-13
<b>Vaccines <sup>(2)</sup></b>													
Gardasil / Gardasil 9	532	469	1,001	378	393	770	860	542	2,173	19	20	30	30
ProQuad / M-M-R II / Varivax	355	399	754	357	383	739	496	405	1,640	4	5	2	3
Roia Ieq	224	123	347	188	130	318	171	162	652	-5	-5	9	9
Pneumovax 23	163	166	329	107	120	228	175	238	641	38	38	44	45
Zostavax	154	160	313	125	149	274	190	221	685	7	7	14	14
<b>Other Pharmaceutical <sup>(3)</sup></b>	<b>1,037</b>	<b>1,116</b>	<b>2,156</b>	<b>1,083</b>	<b>1,128</b>	<b>2,214</b>	<b>1,191</b>	<b>1,172</b>	<b>4,574</b>	<b>-1</b>	<b>0</b>	<b>-3</b>	<b>-2</b>
<b>ANIMAL HEALTH</b>	<b>939</b>	<b>955</b>	<b>1,894</b>	<b>829</b>	<b>900</b>	<b>1,729</b>	<b>865</b>	<b>884</b>	<b>3,478</b>	<b>6</b>	<b>7</b>	<b>10</b>	<b>10</b>
<b>Other Revenues <sup>(4)</sup></b>	<b>310</b>	<b>216</b>	<b>527</b>	<b>379</b>	<b>244</b>	<b>623</b>	<b>228</b>	<b>327</b>	<b>1,178</b>	<b>-11</b>	<b>-5</b>	<b>-15</b>	<b>-5</b>

\* 200% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

<sup>(1)</sup> Only select products are shown.

<sup>(2)</sup> Vaccine sales in 2017 include sales in the European markets that were previously part of the Sanofi Pasteur MSD (SPMSD) joint venture that was terminated on December 31, 2016. Amounts for 2016 reflect supply sales to SPMSD.

<sup>(3)</sup> Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were \$88 million in the first quarter and \$87 million in the second quarter of 2017 and \$103 million, \$91 million, \$135 million and \$126 million for the first, second, third and fourth quarters of 2016, respectively.

<sup>(4)</sup> Other Revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.

**MERCK & CO., INC.**  
**CONSOLIDATED STATEMENT OF INCOME - GAAP**  
**(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)**  
**(UNAUDITED)**  
**Table 1a**

	2017			2016						% Change	
	1Q	2Q	June YTD	1Q	2Q	June YTD	3Q	4Q	Full Year	2Q	June YTD
Sales	\$ 9,434	\$ 9,930	\$ 19,365	\$ 9,312	\$ 9,844	\$ 19,156	\$ 10,536	\$ 10,115	\$ 39,807	1%	1%
Costs, Expenses and Other											
Materials and production	3,015	3,080	6,095	3,572	3,578	7,150	3,409	3,332	13,891	-14%	-15%
Marketing and administrative	2,411	2,438	4,849	2,318	2,458	4,776	2,393	2,593	9,762	-1%	2%
Research and development	1,796	1,749	3,545	1,659	2,151	3,810	1,664	4,650	10,124	-19%	-7%
Restructuring costs	151	166	317	91	134	225	161	265	651	24%	41%
Other (income) expense, net	58	58	117	48	19	67	22	631	720	*	75%
Income (Loss) Before Taxes	2,003	2,439	4,442	1,624	1,504	3,128	2,887	(1,356)	4,659	62%	42%
Income Tax Provision (Benefit)	447	488	935	494	295	789	699	(769)	718		
Net Income (Loss)	1,556	1,951	3,507	1,130	1,209	2,339	2,188	(587)	3,941	61%	50%
Less: Net Income Attributable to Noncontrolling Interests	5	5	11	5	4	9	4	7	21		
Net Income (Loss) Attributable to Merck & Co., Inc.	\$ 1,551	\$ 1,946	\$ 3,496	\$ 1,125	\$ 1,205	\$ 2,330	\$ 2,184	\$ (594)	\$ 3,920	61%	50%
Earnings (Loss) per Common Share Assuming Dilution <sup>(1)</sup>	\$ 0.56	\$ 0.71	\$ 1.27	\$ 0.40	\$ 0.43	\$ 0.83	\$ 0.78	\$ (0.22)	\$ 1.41	65%	53%
Average Shares Outstanding Assuming Dilution <sup>(1)</sup>	2,766	2,752	2,759	2,795	2,789	2,792	2,786	2,755	2,787		
Tax Rate	22.3%	20.0%	21.0%	30.4%	19.6%	25.2%	24.2%	56.7%	15.4%		

\* 100% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

(1) Because the company recorded a net loss in the fourth quarter of 2016, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive.

**MERCK & CO., INC.**  
**GAAP TO NON-GAAP RECONCILIATION**  
**SECOND QUARTER 2016**  
**(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)**  
**(UNAUDITED)**  
**Table 2c**

	<u>GAAP</u>	<u>Acquisition and Divestiture- Related Costs <sup>(1)</sup></u>	<u>Restructuring Costs <sup>(2)</sup></u>	<u>Adjustment Subtotal</u>	<u>Non-GAAP</u>
Materials and production	\$ 3,578	1,120	66	1,186	\$ 2,392
Marketing and administrative	2,458	18	87	105	2,353
Research and development	2,151	207	64	271	1,880
Restructuring costs	134		134	134	—
Income Before Taxes	1,504	(1,345)	(351)	(1,696)	3,200
Income Tax Provision (Benefit)	295	(235) <sup>(3)</sup>	(79) <sup>(3)</sup>	(314)	609
Net Income	1,209	(1,110)	(272)	(1,382)	2,591
Net Income Attributable to Merck & Co., Inc.	1,205	(1,110)	(272)	(1,382)	2,587
Earnings per Common Share Assuming Dilution	\$ 0.43	(0.40)	(0.10)	(0.50)	\$ 0.93
Tax Rate	19.6%				19.0%

Only the line items that are affected by non-GAAP adjustments are shown.

Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Senior management's annual compensation is derived in part using non-GAAP income and non-GAAP EPS. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect \$1.0 billion of expenses for the amortization of intangible assets recognized as a result of acquisitions, as well as \$95 million of intangible asset impairment charges. Amounts included in marketing and administrative expenses reflect integration, transaction and certain other costs related to business acquisitions and divestitures. Amounts included in research and development expenses primarily reflect in-process research and development (IPR&D) impairment charges.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.

(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.

**MERCK & CO., INC.**  
**GAAP TO NON-GAAP RECONCILIATION**  
**SIX MONTHS ENDED JUNE 30, 2016**  
**(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)**  
**(UNAUDITED)**

**Table 2d**

	<b>GAAP</b>	<b>Acquisition and Divestiture- Related Costs <sup>(1)</sup></b>	<b>Restructuring Costs <sup>(2)</sup></b>	<b>Adjustment Subtotal</b>	<b>Non-GAAP</b>
Materials and production	\$ 7,150	2,506	113	2,619	\$ 4,531
Marketing and administrative	4,776	20	90	110	4,666
Research and development	3,810	242	119	361	3,449
Restructuring costs	225		225	225	—
Income Before Taxes	3,128	(2,768)	(547)	(3,315)	6,443
Income Tax Provision (Benefit)	789	(444) <sup>(3)</sup>	(122) <sup>(3)</sup>	(566)	1,355
Net Income	2,339	(2,324)	(425)	(2,749)	5,088
Net Income Attributable to Merck & Co., Inc.	2,330	(2,324)	(425)	(2,749)	5,079
Earnings per Common Share Assuming Dilution	\$ 0.83	(0.84)	(0.15)	(0.99)	\$ 1.82
<b>Tax Rate</b>	<b>25.2%</b>				<b>21.0%</b>

Only the line items that are affected by non-GAAP adjustments are shown.

Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Senior management's annual compensation is derived in part using non-GAAP income and non-GAAP EPS. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect \$2.1 billion of expenses for the amortization of intangible assets recognized as a result of acquisitions, as well as \$347 million of intangible asset impairment charges. Amounts included in marketing and administrative expenses reflect integration, transaction and certain other costs related to business acquisitions and divestitures. Amounts included in research and development expenses primarily reflect in-process research and development (IPR&D) impairment charges.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.

(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.



**MERCK & CO., INC.**  
**FRANCHISE / KEY PRODUCT SALES**  
**SECOND QUARTER 2017**  
**(AMOUNTS IN MILLIONS)**

Table 3a

	Global			U.S.			International		
	2Q 2017	2Q 2016	% Change	2Q 2017	2Q 2016	% Change	2Q 2017	2Q 2016	% Change
<b>TOTAL SALES <sup>(1)</sup></b>	<b>\$ 9,930</b>	<b>\$ 9,844</b>	<b>1</b>	<b>\$ 4,308</b>	<b>\$ 4,507</b>	<b>-4</b>	<b>\$ 5,623</b>	<b>\$ 5,337</b>	<b>5</b>
<b>PHARMACEUTICAL</b>	<b>8,759</b>	<b>8,700</b>	<b>1</b>	<b>3,929</b>	<b>4,169</b>	<b>-6</b>	<b>4,830</b>	<b>4,531</b>	<b>7</b>
<b>Primary Care and Women's Health</b>									
Cardiovascular									
Zetia	367	702	-48	122	457	-73	246	245	
Vytorin	182	293	-38	30	123	-76	152	170	-11
Liptruzet	63	33	88				63	34	87
Adempas	67	40	68				67	40	68
Diabetes									
Januvia	948	1,064	-11	541	631	-14	407	433	-6
Janumet	563	569	-1	248	258	-4	315	312	1
General Medicine & Women's Health									
NuvaRing	199	200		153	149	2	47	51	-8
Implanon / Nexplanon	178	164	9	125	112	12	53	52	1
Follistim AQ	79	73	9	32	20	65	47	53	-12
<b>Hospital and Specialty</b>									
Hepatitis									
Zepatier	517	112	*	256	107	138	261	4	*
HIV									
Isentress/Isentress HD	282	338	-17	136	169	-20	146	169	-14
Hospital Acute Care									
Bridion	163	113	44	54	13	*	109	100	9
Noxafil	155	143	8	77	67	15	78	76	2
Invanz	150	143	5	93	81	14	57	61	-7
Cancidas	112	131	-14	6	6	6	106	125	-15
Cubicin	103	357	-71	53	304	-83	50	53	-5
Primaxin	71	81	-13	1	2	-12	70	79	-13
Immunology									
Remicade	208	339	-39				208	339	-39
Simponi	199	199					199	199	
<b>Oncology</b>									
Keytruda	881	314	180	556	160	*	325	154	111
Emend	143	143		83	93	-10	60	50	20
Temodar	65	73	-12	3	1	*	61	72	-15
<b>Diversified Brands</b>									
Respiratory									
Singulair	203	229	-11	6	7	-11	197	222	-11
Nasonex	85	101	-16	21	29	-27	64	72	-11
Dulera	69	121	-43	63	115	-45	5	6	-17
Other									
Cozaar / Hyzaar	119	132	-10	3	4	-26	116	128	-9
Arcoxia	89	117	-24				89	117	-24
Fosamax	66	73	-10	2		*	65	73	-12
<b>Vaccines <sup>(2)</sup></b>									
Gardasil / Gardasil 9	469	393	19	312	315	-1	156	78	101
ProQuad / M-M-R II / Varivax	399	383	4	341	324	5	58	58	
Pneumovax 23	166	120	38	104	78	34	61	43	44
Zostavax	160	149	7	107	116	-8	52	33	59
RotaTeq	123	130	-5	72	85	-15	51	45	12
<b>Other Pharmaceutical <sup>(3)</sup></b>	<b>1,116</b>	<b>1,128</b>	<b>-1</b>	<b>329</b>	<b>343</b>	<b>-4</b>	<b>789</b>	<b>785</b>	<b>1</b>
<b>ANIMAL HEALTH</b>	<b>955</b>	<b>900</b>	<b>6</b>	<b>270</b>	<b>256</b>	<b>5</b>	<b>685</b>	<b>644</b>	<b>6</b>
<b>Other Revenues <sup>(4)</sup></b>	<b>216</b>	<b>244</b>	<b>-11</b>	<b>109</b>	<b>82</b>	<b>34</b>	<b>106</b>	<b>162</b>	<b>-34</b>

\* 200% or greater

<sup>(1)</sup> Only select products are shown.

<sup>(2)</sup> Vaccine sales in 2017 include sales in the European markets that were previously part of the Sanofi Pasteur MSD (SPMSD) joint venture that was terminated on December 31, 2016. Amounts for 2016 reflect supply sales to SPMSD.

<sup>(3)</sup> Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were \$87 million and \$91 million on a

global basis for second quarter 2017 and 2016, respectively.

<sup>(4)</sup> Other Revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.

---

**MERCK & CO., INC.**  
**FRANCHISE / KEY PRODUCT SALES**  
**JUNE YEAR-TO-DATE 2017**  
**(AMOUNTS IN MILLIONS)**  
**Table 3b**

	Global			U.S.			International		
	June YTD 2017	June YTD 2016	% Change	June YTD 2017	June YTD 2016	% Change	June YTD 2017	June YTD 2016	% Change
<b>TOTAL SALES <sup>(1)</sup></b>	<b>\$ 19,365</b>	<b>\$ 19,156</b>	<b>1</b>	<b>\$ 8,503</b>	<b>\$ 8,728</b>	<b>-3</b>	<b>\$ 10,862</b>	<b>\$ 10,427</b>	<b>4</b>
<b>PHARMACEUTICAL</b>	<b>16,944</b>	<b>16,804</b>	<b>1</b>	<b>7,690</b>	<b>8,082</b>	<b>-5</b>	<b>9,255</b>	<b>8,722</b>	<b>6</b>
<b>Primary Care and Women's Health</b>									
Cardiovascular									
Zetia	701	1,314	-47	233	843	-72	468	471	-1
Vytorin	423	570	-26	120	232	-48	303	337	-10
Liptruzet	112	56	99				112	57	98
Adempas	151	72	109				151	72	109
Diabetes									
Januvia	1,787	1,970	-9	1,048	1,180	-11	740	790	-6
Janumet	1,059	1,075	-2	442	483	-8	617	592	4
General Medicine & Women's Health									
NuvaRing	359	376	-4	265	277	-4	94	99	-5
Implanon / Nexplanon	349	298	17	257	211	22	92	87	6
Follistim AQ	160	167	-4	74	73	2	86	94	-9
<b>Hospital and Specialty</b>									
Hepatitis									
Zepatier	895	161	*	455	156	191	440	5	*
HIV									
Isentress/Isentress HD	587	678	-13	279	331	-16	308	347	-11
Hospital Acute Care									
Bridion	310	204	52	99	18	*	211	186	13
Noxafil	296	288	3	142	137	3	154	150	3
Invanz	286	257	11	175	147	19	111	110	1
Cancidas	233	263	-12	11	10	12	222	254	-12
Cubicin	198	649	-69	107	559	-81	92	89	2
Primaxin	133	154	-14	2	2	-27	132	152	-13
Immunology									
Remicade	437	688	-37				437	688	-37
Simponi	383	387	-1				383	387	-1
<b>Oncology</b>									
Keytruda	1,465	563	160	917	293	*	547	270	102
Emend	276	268	3	169	175	-3	107	94	14
Temodar	130	139	-6	4	5	-16	126	134	-6
<b>Diversified Brands</b>									
Respiratory									
Singulair	389	465	-16	12	24	-50	377	442	-15
Nasonex	224	331	-32	39	141	-72	185	190	-3
Dulera	151	234	-35	139	222	-37	12	12	1
Other									
Cozaar / Hyzaar	231	258	-10	6	9	-39	226	248	-9
Arcoxia	192	228	-16				192	228	-16
Fosamax	127	148	-14	3	1	152	124	147	-16
<b>Vaccines <sup>(2)</sup></b>									
Gardasil / Gardasil 9	1,001	770	30	711	635	12	290	136	114
ProQuad / M-M-R II / Varivax	754	739	2	639	634	1	115	105	10
RotaTeq	347	318	9	250	233	7	96	85	14
Pneumovax 23	329	228	44	219	145	51	110	83	33
Zostavax	313	274	14	216	225	-4	97	49	97
<b>Other Pharmaceutical <sup>(3)</sup></b>	<b>2,156</b>	<b>2,214</b>	<b>-3</b>	<b>657</b>	<b>681</b>	<b>-4</b>	<b>1,498</b>	<b>1,532</b>	<b>-2</b>
<b>ANIMAL HEALTH</b>	<b>1,894</b>	<b>1,729</b>	<b>10</b>	<b>553</b>	<b>489</b>	<b>13</b>	<b>1,341</b>	<b>1,241</b>	<b>8</b>
<b>Other Revenues <sup>(4)</sup></b>	<b>527</b>	<b>623</b>	<b>-15</b>	<b>260</b>	<b>157</b>	<b>65</b>	<b>266</b>	<b>464</b>	<b>-43</b>

\* 200% or greater

<sup>(1)</sup> Only select products are shown.

<sup>(2)</sup> Vaccine sales in 2017 include sales in the European markets that were previously part of the Sanofi Pasteur MSD (SPMSD) joint venture that was terminated on December 31, 2016. Amounts for 2016 reflect supply sales to SPMSD.

<sup>(3)</sup> Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were \$175 million and \$195 million on a global basis for June YTD 2017 and 2016, respectively.

<sup>(4)</sup> Other Revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.

---

**MERCK & CO., INC.**  
**PHARMACEUTICAL GEOGRAPHIC SALES**  
**(AMOUNTS IN MILLIONS)**  
**(UNAUDITED)**  
**Table 3c**

	2017			2016						% Change 2Q
	1Q	2Q	June YTD	1Q	2Q	June YTD	3Q	4Q	Full Year	
<b>TOTAL PHARMACEUTICAL</b>	<b>\$ 8,185</b>	<b>\$ 8,759</b>	<b>\$ 16,944</b>	<b>\$ 8,104</b>	<b>\$ 8,700</b>	<b>\$ 16,804</b>	<b>\$ 9,443</b>	<b>\$ 8,904</b>	<b>\$ 35,151</b>	<b>1</b>
<b>United States</b>	<b>3,761</b>	<b>3,929</b>	<b>7,690</b>	<b>3,913</b>	<b>4,169</b>	<b>8,082</b>	<b>4,710</b>	<b>4,282</b>	<b>17,073</b>	<b>-6</b>
% Pharmaceutical Sales	45.9%	44.9%	45.4%	48.3%	47.9%	48.1%	49.9%	48.1%	48.6%	
<b>Europe <sup>(1)</sup></b>	<b>1,977</b>	<b>2,082</b>	<b>4,059</b>	<b>1,914</b>	<b>1,997</b>	<b>3,911</b>	<b>1,935</b>	<b>1,843</b>	<b>7,689</b>	<b>4</b>
% Pharmaceutical Sales	24.2%	23.8%	24.0%	23.6%	23.0%	23.3%	20.5%	20.7%	21.9%	
<b>Japan</b>	<b>688</b>	<b>818</b>	<b>1,507</b>	<b>620</b>	<b>673</b>	<b>1,293</b>	<b>812</b>	<b>659</b>	<b>2,764</b>	<b>22</b>
% Pharmaceutical Sales	8.4%	9.3%	8.9%	7.7%	7.7%	7.7%	8.6%	7.4%	7.9%	
<b>Asia Pacific</b>	<b>889</b>	<b>946</b>	<b>1,835</b>	<b>806</b>	<b>890</b>	<b>1,696</b>	<b>914</b>	<b>912</b>	<b>3,522</b>	<b>6</b>
% Pharmaceutical Sales	10.9%	10.8%	10.8%	9.9%	10.2%	10.1%	9.7%	10.2%	10.0%	
<b>China</b>	<b>328</b>	<b>353</b>	<b>681</b>	<b>337</b>	<b>353</b>	<b>690</b>	<b>350</b>	<b>333</b>	<b>1,374</b>	<b>0</b>
<b>Latin America</b>	<b>375</b>	<b>462</b>	<b>837</b>	<b>359</b>	<b>430</b>	<b>789</b>	<b>448</b>	<b>538</b>	<b>1,776</b>	<b>7</b>
% Pharmaceutical Sales	4.6%	5.3%	4.9%	4.4%	4.9%	4.7%	4.7%	6.0%	5.1%	
<b>Eastern Europe/Middle East Africa</b>	<b>255</b>	<b>314</b>	<b>569</b>	<b>272</b>	<b>314</b>	<b>586</b>	<b>364</b>	<b>429</b>	<b>1,379</b>	<b>0</b>
% Pharmaceutical Sales	3.1%	3.6%	3.4%	3.4%	3.6%	3.5%	3.9%	4.8%	3.9%	
<b>Canada</b>	<b>182</b>	<b>171</b>	<b>353</b>	<b>147</b>	<b>170</b>	<b>318</b>	<b>184</b>	<b>180</b>	<b>682</b>	<b>0</b>
% Pharmaceutical Sales	2.2%	2.0%	2.1%	1.8%	2.0%	1.9%	1.9%	2.0%	1.9%	
<b>Other</b>	<b>58</b>	<b>37</b>	<b>94</b>	<b>73</b>	<b>57</b>	<b>129</b>	<b>76</b>	<b>61</b>	<b>266</b>	<b>-35</b>
% Pharmaceutical Sales	0.7%	0.4%	0.6%	0.9%	0.7%	0.8%	0.8%	0.7%	0.8%	

<sup>(1)</sup> Europe primarily represents all European Union countries and the European Union accession markets.

MERCK & CO., INC.  
OTHER (INCOME) EXPENSE, NET - GAAP  
(AMOUNTS IN MILLIONS)  
(UNAUDITED)  
Table 4

**OTHER (INCOME) EXPENSE, NET**

	2Q17	2Q16	June YTD 2017	June YTD 2016
INTEREST INCOME	\$ (96)	\$ (78)	\$ (194)	\$ (157)
INTEREST EXPENSE	193	171	375	343
EXCHANGE LOSSES	19	37	11	76
EQUITY (INCOME) LOSS FROM AFFILIATES	(5)	(4)	8	(38)
Other, net	(53)	(107)	(83)	(157)
<b>TOTAL</b>	<b>\$ 58</b>	<b>\$ 19</b>	<b>\$ 117</b>	<b>\$ 67</b>